Unresectable advanced or recurrent gastric cancer
Conditions
Interventions
None listed
Sponsors
Hokkaido Gastrointestinal Cancer Chemotherapy Study Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients pathologically diagnosed with unresectable advanced or recurrent gastric adenocarcinoma or gastroesophageal junction adenocarcinoma 2) Patients confirmed to be HER2-negative and CLDN18.2-positive by pathology 3) Patients who received zolbeximab in combination with fluoropyrimidine antineoplastic agents (5-FU, S-1, capecitabine) and oxaliplatin (cases where administration of other agents was not possible after zolbeximab due to adverse events, etc., despite planned combination therapy are acceptable). Treatment line is not restricted. 4) Patients aged 20 years or older at diagnosis 5) Patients who did not refuse participation in this study
Exclusion criteria
Exclusion criteria: 1) Patients who received combination therapy with fluoropyrimidine antineoplastic agents (5-FU, S-1, capecitabine) or antineoplastic agents other than oxaliplatin and solubeximab, regardless of the route of administration 2) Other patients deemed unsuitable for inclusion in the study by the principal investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety | — |
Secondary
| Measure | Time frame |
|---|---|
| OS, PFS, TTF, best overall response, treatment response predictors, prognostic predictors | — |
Countries
Japan
Contacts
Public ContactKazuaki Harada
Hokkaido University Hospital Tumor Center
Outcome results
None listed